Iodine 131 tositumomab in the treatment of non-Hodgkin’’s lymphoma

ISSN： 1479-6694

Source： Future Oncology, Vol.3, Iss.3, 2007-06, pp. : 255-262

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pralatrexate: treatment of T-cell non-Hodgkin’s lymphoma

By Parker Terri Barbarotta Lisa Foss Francine

Future Oncology, Vol. 9, Iss. 1, 2013-01 ,pp. : 21-29

Future Medicine

Access to resources Recommend Favorite

Antibody–drug conjugates for the treatment of B-cell non-Hodgkin’s lymphoma and leukemia

By Chu Yu-Waye Polson Andrew

Future Oncology, Vol. 9, Iss. 3, 2013-03 ,pp. : 355-368

Future Medicine

Access to resources Recommend Favorite

Primary gastrointestinal non-Hodgkin’s lymphoma: clinicopathological and prognostic analysis

By Wang Tong Gui Wei Shen Quanliang

Medical Oncology, Vol. 27, Iss. 3, 2010-09 ,pp. : 661-666

Humana Press, Inc

Access to resources Recommend Favorite

Primary non-Hodgkin’s lymphoma of the bone: A single institution experience

By Deshmukh C. Bakshi A. Parikh P. Nair R. Pai V. Gupta S. Shaikh A. Muckaden M. Naresh K. Saikia T.

Medical Oncology, Vol. 21, Iss. 3, 2004-09 ,pp. : 263-267

Humana Press, Inc

Access to resources Recommend Favorite

Phase I trial of fludarabine and paclitaxel in non-hodgkin’s lymphoma

By Abbasi Muhammad Sparano Joseph Sarta Catherine Wiernik Peter

Medical Oncology, Vol. 20, Iss. 1, 2003-03 ,pp. : 53-58

Humana Press, Inc

Access to resources Recommend Favorite